Glenmede Trust’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-3,925
| Closed | – | – | 2786 |
|
|
2020
Q1 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 3109 |
|
|
2019
Q4 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 3237 |
|
|
2019
Q3 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 3228 |
|
|
2019
Q2 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 3280 |
|
|
2019
Q1 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 3293 |
|
|
2018
Q4 | $0 | Buy |
+3,925
| New | – | ﹤0.01% | 3159 |
|
|
2017
Q4 | – | Sell |
-3,925
| Closed | – | – | 2917 |
|
|
2017
Q3 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 2971 |
|
|
2017
Q2 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 2734 |
|
|
2017
Q1 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 2839 |
|
|
2016
Q4 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 2741 |
|
|
2016
Q3 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 2759 |
|
|
2016
Q2 | $1K | Hold |
3,925
| – | – | ﹤0.01% | 2515 |
|
|
2016
Q1 | $0 | Hold |
3,925
| – | – | ﹤0.01% | 2799 |
|
|
2015
Q4 | $6K | Hold |
3,925
| – | – | ﹤0.01% | 2235 |
|
|
2015
Q3 | $7K | Hold |
3,925
| – | – | ﹤0.01% | 2217 |
|
|
2015
Q2 | $9K | Hold |
3,925
| – | – | ﹤0.01% | 2131 |
|
|
2015
Q1 | $17K | Hold |
3,925
| – | – | ﹤0.01% | 1989 |
|
|
2014
Q4 | $18K | Hold |
3,925
| – | – | ﹤0.01% | 2056 |
|
|
2014
Q3 | $16K | Hold |
3,925
| – | – | ﹤0.01% | 2010 |
|
|
2014
Q2 | $23K | Buy |
+3,925
| New | +$22.3K | ﹤0.01% | 1834 |
|
Glenmede Trust's TLOG Position: Q2 2020 in Review
Glenmede Trust sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2020, closing a stake of 3,925 shares.
Glenmede Trust first reported a position in TLOG in Q2 2014 and held it in 20 quarters. The position peaked at $23K in Q2 2014. 0 funds tracked by Wall St. Rank hold TLOG as of Q2 2020.
- Glenmede Trust reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2020 after selling out during the quarter.
- Glenmede Trust sold 3,925 TetraLogic Pharmaceuticals Corporation shares in Q2 2020.
- Glenmede Trust first reported a position in TetraLogic Pharmaceuticals Corporation in Q2 2014 and held it in 20 quarters.
- Glenmede Trust's TetraLogic Pharmaceuticals Corporation position peaked at $23K in Q2 2014.
- 0 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2020.
Based on Glenmede Trust's 13F filing for Q2 2020, filed 14 Aug 2020.